dc.contributor.author | Lazaridis, G. | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Lazaridis, G. | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:57Z | |
dc.date.available | 2018-06-22T09:53:57Z | |
dc.date.issued | 2008 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42119 | |
dc.description.abstract | Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or breast-conserving. Moreover, it offers promise to serve as an in vivo chemosensitivity assay and as a powerful predictive factor for outcome. Trastuzumab, a monoclonal antibody targeting an epitope in the extracellular domain of the Human Epidermal Growth Factor Receptor-2 (HER2/erbB-2), was found to be active in HER2-overexpressing metastatic as well as in resected breast cancer when given post-operatively. In this review, we summarise the evidence on the activity and safety of trastuzumab-containing neoadjuvant chemotherapy for the management of women with localised, irresectable or resectable breast cancer. Twenty-three published studies enrolling a total of 585 patients reported pathologic complete responses (pCR) ranging from 7 to 78% with a favourable adverse event profile, data that are presented and discussed in this review. The impact of trastuzumab on long-term outcome, the identification of surrogate biomarkers for sensitivity or resistance to antineoplastic therapy, the optimal schedule of trastuzumab administration and the more active chemotherapeutic regimen for synergism are only a few of the key points needing elucidation so as to rationalise trastuzumab-based approaches. © 2007 Elsevier Ireland Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Critical reviews in oncology/hematology | en |
dc.subject | Female | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Doxorubicin | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Breast neoplasms | en |
dc.subject | Carboplatin | en |
dc.subject | Paclitaxel | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Arthralgia | en |
dc.subject | Constipation | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug safety | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Mucosa inflammation | en |
dc.subject | Navelbine | en |
dc.subject | Neutropenia | en |
dc.subject | Stomatitis | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Cardiotoxicity | en |
dc.subject | Disease free survival | en |
dc.subject | Review | en |
dc.subject | Docetaxel | en |
dc.subject | Overall survival | en |
dc.subject | Epirubicin | en |
dc.subject | Sepsis | en |
dc.subject | Antibodies | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Side effect | en |
dc.subject | Monoclonal antibody | en |
dc.subject | Breast cancer | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Nausea | en |
dc.subject | Lung embolism | en |
dc.subject | Treatment response | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Drug potentiation | en |
dc.subject | Cancer regression | en |
dc.subject | Granulocyte macrophage colony stimulating factor | en |
dc.subject | Fluorescence in situ hybridization | en |
dc.subject | Skin toxicity | en |
dc.subject | Edema | en |
dc.subject | Headache | en |
dc.subject | Asthenia | en |
dc.subject | Clinical trials as topic | en |
dc.subject | Death | en |
dc.subject | Hypersensitivity reaction | en |
dc.subject | Dehydration | en |
dc.subject | Monoclonal | en |
dc.subject | Trastuzumab | en |
dc.subject | Neuropathy | en |
dc.subject | Anthracycline | en |
dc.subject | Epidermal growth factor receptor 2 | en |
dc.subject | Erbb-2 | en |
dc.subject | Receptor | en |
dc.subject | Early cancer | en |
dc.subject | Loading drug dose | en |
dc.subject | Rash | en |
dc.subject | Inoperable cancer | en |
dc.subject | Anasarca | en |
dc.subject | Chemosensitivity | en |
dc.subject | Drug synergism | en |
dc.subject | Heart atrium fibrillation | en |
dc.subject | Micrometastasis | en |
dc.subject | Neoadjuvant chemotherapy | en |
dc.subject | Neoadjuvant therapy | en |
dc.title | Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.critrevonc.2007.07.002 | |
dc.description.volume | 66 | |
dc.description.issue | 1 | |
dc.description.startingpage | 31 | |
dc.description.endingpage | 41 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |